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In a recent issue, Cellular and Molecular Life Sciences
published on the combination of photodynamic therapy
(PDT) and anti-angiogenesis for the treatment of cancer
[1]. In this paper, Bhuvaneswari and colleagues elegantly
review this field. The idea behind combining these two
therapeutic strategies is based on the observation that PDT
can lead to vessel closure, and hence hypoxia, as well as
other tissue damage resulting in inflammation. This com-
bination of hypoxia and inflammation can in turn cause the
enhanced release of angiogenic growth factors (vascular
endothelial growth factor, VEGF) followed by the
regrowth of the targeted neoplastic tissue. Thus, it appeared
logical to try to block the VEGF pathways after PDT, for
instance by applying antibodies against VEGF. This type of
combination therapy is not limited to the treatment of
cancer. Indeed, for the treatment of certain forms of exu-
dative macular degeneration, recently published results
from a phase II clinical study demonstrate great promise
for the combination of PDT (Visudyne) together with anti-
VEGF-A therapy using humanized antibody fragments
(Lucentis). PDT as a monotherapy has clearly been shown
to be effective in treating some early stage superficial
cancers. However, for more advanced cancers, where PDT
monotherapy appears to be less effective, the usefulness of
the photodynamic approach followed by anti-VEGF ther-
apy has not yet been extensively demonstrated in the clinic.
For the treatment of advanced cancer, there has been
recently significant interest in the use of vascular normal-
ization [2] by the application of anti-angiogenesis
compounds like the above-mentioned anti-VEGFs. Such
inhibitors of angiogenesis can, at least in part, reverse the
situation of abnormal leaky and tortuous vasculature in the
tumor to make a more normal vascular phenotype. This
vascular normalization has been shown in tumor models to
normalize both the interstitial perivascular pressure as well
as the tissue oxygenation. The transient normalization of
the abnormal structure and function of advanced tumor
vasculature following the application of angiogenesis
inhibitors was put forward as the explanation of the
sometimes spectacular beneficial effects observed when
applying angiostasis prior to chemotherapy or radiation
therapy.
This induced angiogenesis inhibition leads to (1) tem-
porarily normalized tissue pressure and therefore to the
possibility of enhanced exposure and sensitivity of the
tumor cells to chemotherapeutic compounds, and (2)
enhanced tissue oxygenation, making the tumor cells more
vulnerable to radiotherapy [2, 3]. It should be noted that
this normalization has the potential to reduce the hetero-
geneous features, of the vasculature in particular, which
characterize virtually all cancers. This is of importance
because heterogeneity of cancer properties may underlie
the failure of many current treatment regimens including
anti-angiogenesis therapy itself. The efficacy of PDT for
the destruction of tumor tissue is based on intravascular
thrombotic events and/or a direct destruction of cells in
the perivascular tumor tissue, both through mechanisms
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involving photochemical induction of toxic reactive oxy-
gen species. Hence it is not unreasonable to expect that
normalization of the oxygen pressure in the tumor tissue
following anti-angiogenesis induced vascular normaliza-
tion, should also lead to an increased and more
homogenous effect of oxygen-dependent PDT. Conse-
quently, it may be hypothesized that anti-angiogenesis
treatment might be effectively scheduled not only after
PDT but also in a carefully chosen time gap, possibly of a
few days, before PDT [3]. The timing of the normalization
window will probably depend on the mechanism of the
angiogenesis inhibitor used. Of course, the carefully opti-
mized combination of multiple anti-angiogenesis agents
acting via different pathways may be even more efficient
for this purpose than the single-agent approach as discussed
above. The time-dependent biodistribution and mechanism
of action of the photosensitizer are among the other
important factors to be optimized in the combination
therapy.
As is clear from the Bhuvaneswari paper, efforts to
schedule the anti-angiogenesis treatment before PDT as a
treatment of malignancies are very sparse, and essentially
restricted to case reports. An example of such a case report,
in which anti-angiogenesis is applied clinically prior to
PDT, has been provided recently by Sagong et al. [4]. This
paper discusses two patients with circumscribed choroidal
hemangioma, who were treated with intravitreal injection
of Avastin and subsequent PDT with Visudyne. The result
of this clinical application on a very limited number of
patients turned out to be very successful indeed, since
complete regression of the lesions was observed in these
patients for 6–9 months. Furthermore, the reported
improved visual acuity was accompanied by complete
resorption of subretinal fluid and macular edema.
If, however, following the normalization of the vascu-
lature induced by the anti-VEGF therapy, the exposure to
these compounds is excessively prolonged, this may lead to
a reduction of the blood vessel density, and even less
provision to the tumor of oxygen and therapeutics. Thus it
is proposed here that PDT is to be applied in the time
window where blood vessels are ‘‘normalized’’, i.e., well
before vessel number reduction, when the tissue oxygen
levels are still relatively high.
Some reports have suggested that PDT following (or
occurring simultaneously with) angiogenesis inhibition
would be equally effective, or possibly less beneficial, than
PDT prior to anti-angiogenic therapy [5]. However, these
studies were not specifically designed with the goal of
benefiting from vascular normalization, and the angiogen-
esis inhibitor may consequently have been applied outside
the optimal time slot of vascular normalization and
enhanced oxygenation.
Finally, it should be mentioned that the major current
challenge for the improvement of PDT is the introduction
of better targeting of photosensitizers in order to more
selectively treat the diseased tissues. Still, the improvement
of PDT efficacy through vascular normalization and the
subsequent homogenization may also be very useful, in
particular for the application of PDT to cases of advanced
cancer. We favor the view that there is a window of
opportunity for PDT following anti-angiogenesis vascular
normalization. It should be understood that systemic
treatment with angiogenesis inhibitors can have side-
effects such as anti-thrombotic activity and hypertension
[6]. It is to be envisioned that co-treatment for such indi-
cations is a valid option [7]. We would furthermore like to
underline that the anti-angiogenesis modality in this com-
bination therapy may well be applied in the form of a drug
cocktail that interacts via multiple complementary path-
ways [8], and that the optimal combination treatment
conditions may also depend on such parameters as the
proliferation of the tumor blood vessels. It is for these
reasons that we conclude here that more research is needed
to systematically test the optimal relative timing in the
combination of anti-angiogenesis therapy and PDT for the
treatment of cancer.
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